戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  90.4% (clindamycin) to 100% (vancomycin and gatifloxacin).
2 cal and clinical effectiveness compared with gatifloxacin.
3 in high-level resistance to moxifloxacin and gatifloxacin.
4  (34%) to moxifloxacin, and 3 of 13 (23%) to gatifloxacin.
5 ized to 1 of 4 antibiotics (azithromycin 1%, gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%) an
6 yes were injected intravitreally with 0.1 mL gatifloxacin (0.3%), vancomycin (1.0%), either antibioti
7 hout stratification to 7 days of either oral gatifloxacin (10 mg/kg per day) or intravenous ceftriaxo
8 tention-to-treat population (120 assigned to gatifloxacin, 119 to ceftriaxone).
9 oxacin, 50 microM; moxifloxacin, 129 microM; gatifloxacin, 130 microM; levofloxacin, 915 microM; and
10 tivally prior to or coapplied topically with gatifloxacin 16 hours after infection.
11                            Patients received gatifloxacin 400 mg either by the intravenous or NG rout
12 was compared with a 4-month regimen in which gatifloxacin (400 mg per day) was substituted for ethamb
13                                          The gatifloxacin 5-microg disk test produced zone diameters
14 .5%; oxacillin, 54.7%; ciprofloxacin, 51.0%; gatifloxacin, 51.0%; and moxifloxacin, 47.0%.
15 ted the efficacy of long-term treatment with gatifloxacin, a bactericidal antibiotic known to be effe
16 riteria and quality control were studied for gatifloxacin, a new 8-methoxy fluoroquinolone, tested ag
17                            Ciprofloxacin and gatifloxacin also inhibited hOAT3.
18        Control quinolones (ciprofloxacin and gatifloxacin) also performed at a similarly high level o
19  the United States) were also tested against gatifloxacin and 12 other antimicrobial agents.
20  historic BI/NAP1 isolates were resistant to gatifloxacin and moxifloxacin (P<0.001).
21   High-level resistance (MIC, >32 mug/ml) to gatifloxacin and moxifloxacin was documented for 46.7% o
22                                Resistance to gatifloxacin and moxifloxacin was more common in current
23 , including 15 (39.5%) isolates resistant to gatifloxacin and moxifloxacin, members of the C-8-methox
24  serve as an ophthalmic delivery vehicle for gatifloxacin and to evaluate its in vitro and in vivo de
25 ials were the newer quinolones (garenoxacin, gatifloxacin, and levofloxacin, each with a MIC at which
26 ysis, ophthalmic solutions of ciprofloxacin, gatifloxacin, and moxifloxacin are now approved for all
27 c anti-infective solutions of ciprofloxacin, gatifloxacin, and moxifloxacin were constructed and comp
28                                              Gatifloxacin appears to be a potent anti-Haemophilus flu
29 y released fluoroquinolones moxifloxacin and gatifloxacin are reviewed in terms of their clinical pro
30 comitant gastric tube feeding did not affect gatifloxacin bioavailability (interrupted tube feeds: 98
31 is needed to identify those patients in whom gatifloxacin bioavailability is reduced and for whom an
32 ough concomitant tube feeding did not affect gatifloxacin bioavailability, critical illness resulted
33 ness and concomitant gastric tube feeding on gatifloxacin bioavailability.
34  [range 24.1 to 63.1] microg x h/mL, p =.60) gatifloxacin (bioavailability: 98.5% [range 61.1% to 119
35                                 Serial serum gatifloxacin concentrations (from 5 mins to 24 hrs) were
36 G) for >or=12 hrs were randomized to receive gatifloxacin concurrently with continuous tube feeding o
37 ssessed the efficacy and safety of a 4-month gatifloxacin-containing regimen for treating rifampin-se
38                  Subjects received 400 mg of gatifloxacin daily during an initial 2-week course of th
39  ciprofloxacin (day 4, 49%; day 5, 61%), and gatifloxacin (day 7, 79%) were within the 95% CI for pro
40 educed and for whom an empirical increase in gatifloxacin dose should be considered.
41 , ciprofloxacin, norfloxacin, ofloxacin, and gatifloxacin exhibited concentration-dependent inhibitio
42 od culture, only two (3%) of 58 who received gatifloxacin failed treatment versus 15 (23%) of 65 who
43 lation, 16 (26%) of 62 patients who received gatifloxacin failed treatment, compared with four (7%) o
44 er fluoroquinolones, including levofloxacin, gatifloxacin, gemifloxacin, and garenoxacin (BMS 284756)
45 gorical results for amikacin, ciprofloxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, merope
46                                          The gatifloxacin (GFX) solubility-enhancing property of a si
47 y: moxifloxacin (MXF), levofloxacin (LVX) or gatifloxacin (GFX).
48 ermore, topical coapplication of MMP13i with gatifloxacin greatly improved disease outcomes, includin
49 istant isolates, the MICs for ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, and trovaflox
50 events at two years were 23.7 percent in the gatifloxacin group and 25.1 percent in the placebo group
51 h high-level resistance to ciprofloxacin and gatifloxacin had emerged.
52               18 (15%) patients who received gatifloxacin had treatment failure, compared with 19 (16
53                             Moxifloxacin and gatifloxacin have improved potency and are able to overc
54 arly intravitreal injection of vancomycin or gatifloxacin improved the therapeutic outcome of B. cere
55  variability that may complicate the role of gatifloxacin in sequential intravenous-to-oral therapy.
56 r enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance an
57 CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezolid, meropenem, penici
58                                              Gatifloxacin (MIC at which 90% of the isolates are inhib
59                                              Gatifloxacin (MIC50, 0.008 microg/ml) was slightly more
60  for H. influenzae strains, corresponding to gatifloxacin MICs of 0.008 or 0.016 microg/ml.
61                                      Neither gatifloxacin nor vancomycin was toxic to retinal cells i
62                             Moxifloxacin and gatifloxacin offer improved spectrum of activity, increa
63                            Combining topical gatifloxacin or ofloxacin with intracameral agent was no
64 were resistant to ciprofloxacin (p = 0.001), gatifloxacin (p = 0.003), and ofloxacin (p = 0.002) comp
65                        Compared with topical gatifloxacin, prophylaxis using topical aminoglycoside w
66                                         Only gatifloxacin reached aqueous concentrations greater than
67 fluoroquinolone-containing (moxifloxacin and gatifloxacin) regimens have failed to shorten duration o
68 t performed well, detecting 52 of 60 (86.7%) gatifloxacin-resistant isolates and 22 of 23 moxifloxaci
69                                          The gatifloxacin susceptibility breakpoint proposed for nonf
70                                              Gatifloxacin use was associated with the highest rate (R
71  trial with ceftriaxone, the fluoroquinolone gatifloxacin was associated with equivalent or better fe
72 ccumulation of other fluoroquinolones (e.g., gatifloxacin) was also slightly enhanced.
73 hat the strains resistant to levofloxacin or gatifloxacin were associated with higher colony counts t
74 eneration fluoroquinolones, moxifloxacin and gatifloxacin, were introduced in 2003 promising improved
75               Resistance to moxifloxacin and gatifloxacin when tested at 2 mug/mL was low in all coun
76                          All trials compared gatifloxacin with 1 of the following comparator drugs: c
77 veness of early treatment with vancomycin or gatifloxacin, with or without dexamethasone, for experim
78   Eyes treated at 2 hours with vancomycin or gatifloxacin, with or without dexamethasone, maintained
79 e and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceft